Document Preview Unavailable

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

Canessa Clementina; Iacopelli Jessica; Pecoraro, Antonio; Spadaro Giuseppe; Matucci, Andrea; et al.  International Journal of Immunopathology and Pharmacology Vol. 30, Iss. 1,  (Mar 2017): 73-82.

You might have access to this document